Genprex Announces Presentation of Acclaim-3 Clinical Trial Design at ASCO 2025
Genprex, Inc., a pioneering company in gene therapy, has made headlines by securing a spot to present its innovative trial design at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting in 2025. This landmark event is set to be held from May 30 through June 3 in Chicago, Illinois, as well as virtually, providing a platform for significant advancements in oncology. Genprex’s research centers around its lead drug known as Reqorsa® Gene Therapy, aimed at treating extensive stage small cell lung cancer (ES-SCLC).
During the ASCO meeting, Genprex will share insights into the Acclaim-3 Phase 1/2 clinical trial, which evaluates the efficacy of Reqorsa in conjunction with Tecentriq® maintenance therapy. This combination aims to enhance the treatment landscape for patients suffering from this aggressive form of lung cancer. Ryan Confer, the President and CEO of Genprex, expressed immense enthusiasm about being selected for this prestigious event, highlighting the opportunity to engage with industry peers who are equally devoted to advancing cancer care.
The presentation will focus on the details of the trial's design, which is critical for setting the stage for upcoming discussions regarding the evolving fields of cancer treatment. Researchers and clinicians from around the globe are keenly interested in the outcomes of such trials, as they have the potential to reshape therapeutic approaches for patients with few options.
The trial is designed to assess the safety and effectiveness of combining the gene therapy quaratusugene ozeplasmid (Reqorsa) with the immune checkpoint inhibitor atezolizumab (Tecentriq). Notably, both drug candidates have shown promising results in early studies. The Acclaim-3 trial is a crucial step in Genprex's strategy to offer more effective treatments for patients with extensive stage small cell lung cancer, who often experience limited therapeutic options.
Investors and stakeholders have a vested interest in the outcomes of such trials, especially given Genprex’s commitment to innovation in the oncology space. With both a Fast Track and FDA Orphan Drug designation for its SCLC program, Genprex is on the cutting edge of developing comprehensive solutions to combat cancer. Their ongoing work not only focuses on oncology but also extends into the treatment of diabetes through groundbreaking gene therapy approaches, showcasing the Company’s commitment to addressing critical health challenges facing broad patient populations.
The ASCO Annual Meeting, renowned for featuring cutting-edge research and clinical advancements, offers an excellent opportunity for Genprex to present its findings and align with other leaders dedicated to improving cancer care. Attendees will have the chance to view the detailed trial design during a poster session scheduled for May 31, 2025, from 1:30 PM to 4:30 PM CT, presented by Dr. Bo Wang from Oncology Associates of Oregon.
Genprex's efforts to amplify awareness around the trial’s findings reflect its broader mission to revolutionize treatment modalities for serious illnesses. For those keen to stay updated on Genprex's journey, they encourage interested parties to subscribe to their email alerts and follow their progress through their social media platforms. As the field of cancer treatment evolves, collaborations and innovations such as those presented by Genprex play an essential role in ensuring the best possible outcomes for patients in need.
In summary, Genprex’s participation in the 2025 ASCO Annual Meeting marks a pivotal moment for the company as they unveil the trial design for Acclaim-3, showcasing their commitment to developing innovative therapies for lung cancer. With the support of the medical community and ongoing investor interest, Genprex is well-positioned to contribute significantly to the future of cancer care.
For continuous updates and insights into their latest developments, Genprex encourages all stakeholders to stay connected through their various communication channels.
During the ASCO meeting, Genprex will share insights into the Acclaim-3 Phase 1/2 clinical trial, which evaluates the efficacy of Reqorsa in conjunction with Tecentriq® maintenance therapy. This combination aims to enhance the treatment landscape for patients suffering from this aggressive form of lung cancer. Ryan Confer, the President and CEO of Genprex, expressed immense enthusiasm about being selected for this prestigious event, highlighting the opportunity to engage with industry peers who are equally devoted to advancing cancer care.
The presentation will focus on the details of the trial's design, which is critical for setting the stage for upcoming discussions regarding the evolving fields of cancer treatment. Researchers and clinicians from around the globe are keenly interested in the outcomes of such trials, as they have the potential to reshape therapeutic approaches for patients with few options.
The trial is designed to assess the safety and effectiveness of combining the gene therapy quaratusugene ozeplasmid (Reqorsa) with the immune checkpoint inhibitor atezolizumab (Tecentriq). Notably, both drug candidates have shown promising results in early studies. The Acclaim-3 trial is a crucial step in Genprex's strategy to offer more effective treatments for patients with extensive stage small cell lung cancer, who often experience limited therapeutic options.
Investors and stakeholders have a vested interest in the outcomes of such trials, especially given Genprex’s commitment to innovation in the oncology space. With both a Fast Track and FDA Orphan Drug designation for its SCLC program, Genprex is on the cutting edge of developing comprehensive solutions to combat cancer. Their ongoing work not only focuses on oncology but also extends into the treatment of diabetes through groundbreaking gene therapy approaches, showcasing the Company’s commitment to addressing critical health challenges facing broad patient populations.
The ASCO Annual Meeting, renowned for featuring cutting-edge research and clinical advancements, offers an excellent opportunity for Genprex to present its findings and align with other leaders dedicated to improving cancer care. Attendees will have the chance to view the detailed trial design during a poster session scheduled for May 31, 2025, from 1:30 PM to 4:30 PM CT, presented by Dr. Bo Wang from Oncology Associates of Oregon.
Genprex's efforts to amplify awareness around the trial’s findings reflect its broader mission to revolutionize treatment modalities for serious illnesses. For those keen to stay updated on Genprex's journey, they encourage interested parties to subscribe to their email alerts and follow their progress through their social media platforms. As the field of cancer treatment evolves, collaborations and innovations such as those presented by Genprex play an essential role in ensuring the best possible outcomes for patients in need.
In summary, Genprex’s participation in the 2025 ASCO Annual Meeting marks a pivotal moment for the company as they unveil the trial design for Acclaim-3, showcasing their commitment to developing innovative therapies for lung cancer. With the support of the medical community and ongoing investor interest, Genprex is well-positioned to contribute significantly to the future of cancer care.
For continuous updates and insights into their latest developments, Genprex encourages all stakeholders to stay connected through their various communication channels.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.